FTO and neoplasm: Conversely, METTL16 mediates m6A modification at the 3’ UTR region of prostate transmembrane protein, androgen-induced 1 (PMEPA1) mRNA, reducing PMEPA1 mRNA stability and decreasing its protein expression, thereby inhibiting cell proliferation.17 However, FTO exhibits a dual role in BC, acting as both an oncogenic and a tumor-suppressive factor.